Drugs / teraplizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05898373 | Jun 2023 → Jun 2025 | salivary gland cancer | Peking Union Medical College | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06235242 | Feb 2024 → Dec 2025 | non-small cell lung carcinoma | Grit Biotechnology | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | teraplizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898373 ↗ |